Open Access · CC BY-NC 4.0
EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?
Liver Cancer · 05.09.2026 · 15 (5) · 649-659
DOI: 10.1159/lic/admag018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 27.10.2026. Verfasst von Masatoshi Kudo. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kudo, M. (2026). EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?. Liver Cancer, 15(5), 649-659. https://doi.org/10.1159/lic/admag018
Vancouver
Kudo M. EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?. Liver Cancer. 2026;15(5):649-659. doi:10.1159/lic/admag018
BibTeX
@article{Kudo2026,
author = {Kudo, Masatoshi},
title = {EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?},
journal = {Liver Cancer},
year = {2026},
volume = {15},
number = {5},
pages = {649--659},
doi = {10.1159/lic/admag018}
}
EUVIMED